Promising data for ziftomenib in relapsed/refractory NPM1-mutated AML Presented ByDr Amir Fathi, Massachusetts General Hospital, Massachusetts, USA TrialPhase 1/2, KOMET-001 ConferenceEHA 2023 2 August, 2023 16:51